Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lynn Malec

Pediatric Hematology-Oncology Milwaukee, WI Medical Doctor

NPI 1629222450 CMS profile 1310903

9000 W Wisconsin Ave, Milwaukee, WI 53226

Open in the dashboard

General payments

$663,866

420 records reported · program years 2019–2025

Research payments

$6,520

Paid to them · 11 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$697,801 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Lynn Malec of Milwaukee, WI is reported in the CMS Open Payments database as having received $663,866 across 420 general payments and $6,520 in research payments paid to them. Separately, studies naming them as principal investigator received $697,801 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Pediatric Hematology-Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $118,843 69
2025 Research $2,250 6
2024 General $140,312 90
2023 General $163,991 92
2023 Research $1,750 2
2022 General $100,687 53
2021 General $39,367 27
2020 General $47,038 25
2019 General $53,628 64
2019 Research $2,520 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lynn Malec
  • Pediatric Hematology-Oncology median
  • Middle half of Pediatric Hematology-Oncology
  • National median

In program year 2025, general payments to Lynn Malec were reported at $118,843. Among 1,352 Pediatric Hematology-Oncology profiles paid that year, the median was $204 and the middle half received between $80 and $2,819.

Show as a table
Year Lynn Malec Pediatric Hematology-Oncology median Middle half National median
2019 $53,628 $184 $69–$2,094 $163
2020 $47,038 $220 $37–$3,941 $114
2021 $39,367 $366 $63–$4,909 $132
2022 $100,687 $181 $66–$2,775 $149
2023 $163,991 $175 $62–$2,600 $160
2024 $140,312 $227 $66–$2,992 $164
2025 $118,843 $204 $80–$2,819 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genzyme Corporation $309,620 147 payments
  2. CSL Behring $104,885 86 payments
  3. Bioverativ Therapeutics Inc. $44,208 38 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $42,718 23 payments
  5. Sanofi-Aventis U.S. LLC $31,811 12 payments
  6. Genentech USA, Inc. $29,149 35 payments
  7. Swedish Orphan Biovitrum AB $24,106 6 payments
  8. Sanofi US Services Inc. $23,170 2 payments
  9. Novo Nordisk Inc $14,476 12 payments
  10. BioMarin Pharmaceutical Inc. $11,878 20 payments
  11. Other $27,846 39 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $286,687 55 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $261,691 90 payments
  3. Travel and Lodging $79,610 116 payments
  4. Honoraria $15,283 4 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $10,817 1 payment
  6. Food and Beverage $9,574 142 payments
  7. Education $192 8 payments
  8. Gift $12 4 payments
Products named General payments · program years 2019–2025
  1. ALTUVIIIO $73,013 28 payments
  2. HEMGENIX $55,060 37 payments
  3. ALPROLIX Hematology $43,079 23 payments
  4. HEMLIBRA $29,149 35 payments
  5. ELOCTATE Hematology $28,153 15 payments
  6. Idelvion $28,152 23 payments
  7. ELOCTATE Hematology $22,126 5 payments
  8. ALPROLIX Hematology $21,775 21 payments
  9. ELOCTATE Hematology $12,386 10 payments
  10. ADVATE $8,527 4 payments
  11. Other $35,560 62 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Genzyme Corporation $4,000 8 payments
  2. Bioverativ Therapeutics Inc. $2,520 3 payments

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$469,805

Medicare's payments for the services billed

Medicare patients

16

Average age 71

Services billed

86,100

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 75%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ALTUVIIIO
  • GENZYME CORPORATION $30,429
$30,429 — —
HEMGENIX
  • CSL Behring $19,906
$19,906 — —
ELOCTATE
  • GENZYME CORPORATION $11,971
$11,971 — —
ALPROLIX
  • GENZYME CORPORATION $11,512
$11,512 — —
HEMLIBRA
  • Genentech USA, Inc. $6,740
$6,740 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

431 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Hematology-Oncology in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record